Skip to main content
Erschienen in: Journal of Gastroenterology 8/2019

04.03.2019 | Original Article—Liver, Pancreas, and Biliary Tract

Noninvasive diagnostic criteria for nonalcoholic steatohepatitis based on gene expression levels in peripheral blood mononuclear cells

verfasst von: Akira Kado, Takeya Tsutsumi, Kenichiro Enooku, Hidetaka Fujinaga, Kazuhiko Ikeuchi, Kazuya Okushin, Kyoji Moriya, Hiroshi Yotsuyanagi, Kazuhiko Koike

Erschienen in: Journal of Gastroenterology | Ausgabe 8/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

Nonalcoholic fatty liver disease (NAFLD) consists of nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH); the latter progresses to liver cirrhosis and hepatocellular carcinoma. Discriminating NASH from NAFL typically involves liver biopsy. The mechanism of NASH progression is unclear but may involve immunological pathways. In this study, we examined expression levels of cytokine- and chemokine-encoding genes in peripheral blood mononuclear cells (PBMCs) from NAFLD patients and established immunological criteria for discriminating NASH from NAFL.

Methods

PBMCs were obtained from 54 patients diagnosed histologically with NAFLD (NAFL, 18; NASH, 36). mRNA was extracted from PBMCs, and expression levels of cytokine- and chemokine-encoding genes were determined by quantitative real-time PCR. Statistical analysis was performed by nonparametric test.

Results

Expression levels of interferon (IFN)γ, interleukin (IL)2, IL15, C–C-motif chemokine ligand (CCL)2, IL10, and C-X-C-motif chemokine ligand (CXCL)11 were significantly upregulated in NASH patients compared with NAFL patients. Moreover, their expression levels were positively correlated with the degree of ballooning of hepatocytes but not of steatosis or lobular inflammation. We focused on those encoding IL10, IFNγ, and CCL2, and developed a scoring system to discriminate NASH from NAFL. The discriminatory power of the criteria was validated in an independent cohort.

Conclusions

Expression levels of the cytokine- and chemokine-encoding genes in PBMCs were positively correlated with ballooning, suggesting their utility for the diagnosis of NASH. The data indicate that peripheral as well as intrahepatic immunity is involved in the progression of NASH. Our findings afford new insight into immunological mechanisms of NASH and will facilitate its noninvasive diagnosis.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Eguchi Y, Hyogo H, Ono M, et al. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. J Gastroenterol. 2012;47:586–95.CrossRefPubMed Eguchi Y, Hyogo H, Ono M, et al. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. J Gastroenterol. 2012;47:586–95.CrossRefPubMed
2.
Zurück zum Zitat Adams LA, Waters OR, Knuiman MW, et al. NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study. Am J Gastroenterol. 2009;104:861–7.CrossRefPubMed Adams LA, Waters OR, Knuiman MW, et al. NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study. Am J Gastroenterol. 2009;104:861–7.CrossRefPubMed
3.
Zurück zum Zitat Hamaguchi M, Kojima T, Takeda N, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med. 2005;143:722–8.CrossRefPubMed Hamaguchi M, Kojima T, Takeda N, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med. 2005;143:722–8.CrossRefPubMed
4.
Zurück zum Zitat Baffy G, Brunt EM, Caldwell SH. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J Hepatol. 2012;56:1384–91.CrossRefPubMed Baffy G, Brunt EM, Caldwell SH. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J Hepatol. 2012;56:1384–91.CrossRefPubMed
5.
Zurück zum Zitat Caldwell SH, Hespenheide EE. Subacute liver failure in obese women. Am J Gastroenterol. 2002;97:2058–62.CrossRefPubMed Caldwell SH, Hespenheide EE. Subacute liver failure in obese women. Am J Gastroenterol. 2002;97:2058–62.CrossRefPubMed
6.
Zurück zum Zitat Targher G, Bertolini L, Padovani R, et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care. 2007;30:1212–8.CrossRefPubMed Targher G, Bertolini L, Padovani R, et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care. 2007;30:1212–8.CrossRefPubMed
7.
Zurück zum Zitat Mahady SE, George J. Exercise and diet in the management of nonalcoholic fatty liver disease. Metabolism. 2016;65:1172–82.CrossRefPubMed Mahady SE, George J. Exercise and diet in the management of nonalcoholic fatty liver disease. Metabolism. 2016;65:1172–82.CrossRefPubMed
8.
Zurück zum Zitat Maher JJ, Leon P, Ryan JC. Beyond insulin resistance: innate immunity in nonalcoholic steatohepatitis. Hepatology. 2008;48:670–8.CrossRefPubMed Maher JJ, Leon P, Ryan JC. Beyond insulin resistance: innate immunity in nonalcoholic steatohepatitis. Hepatology. 2008;48:670–8.CrossRefPubMed
9.
Zurück zum Zitat Sutti S, Jindal A, Locatelli I, et al. Adaptive immune responses triggered by oxidative stress contribute to hepatic inflammation in NASH. Hepatology. 2014;59:886–97.CrossRefPubMed Sutti S, Jindal A, Locatelli I, et al. Adaptive immune responses triggered by oxidative stress contribute to hepatic inflammation in NASH. Hepatology. 2014;59:886–97.CrossRefPubMed
11.
Zurück zum Zitat Gadd VL, Skoien R, Powell EE, et al. The portal inflammatory infiltrate and ductular reaction in human nonalcoholic fatty liver disease. Hepatology. 2014;59:1393–405.CrossRefPubMed Gadd VL, Skoien R, Powell EE, et al. The portal inflammatory infiltrate and ductular reaction in human nonalcoholic fatty liver disease. Hepatology. 2014;59:1393–405.CrossRefPubMed
12.
Zurück zum Zitat Boursier J, Mueller O, Barret M, et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology. 2016;63:764–75.CrossRefPubMed Boursier J, Mueller O, Barret M, et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology. 2016;63:764–75.CrossRefPubMed
13.
Zurück zum Zitat Liang W, Lindeman JH, Menke AL, et al. Metabolically induced liver inflammation leads to NASH and differs from LPS-or IL-1β-induced chronic inflammation. Lab Invest. 2014;94:491–502.CrossRefPubMed Liang W, Lindeman JH, Menke AL, et al. Metabolically induced liver inflammation leads to NASH and differs from LPS-or IL-1β-induced chronic inflammation. Lab Invest. 2014;94:491–502.CrossRefPubMed
14.
Zurück zum Zitat Okushin K, Tsutsumi T, Enooku K, et al. The intrahepatic expression levels of bile acid transporters are inversely correlated with the histological progression of nonalcoholic fatty liver disease. J Gastroenterol. 2015;51:808–18.CrossRefPubMed Okushin K, Tsutsumi T, Enooku K, et al. The intrahepatic expression levels of bile acid transporters are inversely correlated with the histological progression of nonalcoholic fatty liver disease. J Gastroenterol. 2015;51:808–18.CrossRefPubMed
15.
Zurück zum Zitat Yu S, Allen JN, Dey A, et al. Immunology in the liver—from homeostasis to disease. J Immunol. 2016;197:256–65.CrossRefPubMed Yu S, Allen JN, Dey A, et al. Immunology in the liver—from homeostasis to disease. J Immunol. 2016;197:256–65.CrossRefPubMed
16.
Zurück zum Zitat Xu L, Kitade H, Ni Y, et al. Roles of chemokines and chemokine receptors in obesity-associated insulin resistance and nonalcoholic fatty liver disease. Biomolecules. 2015;5:1563–79.CrossRefPubMedPubMedCentral Xu L, Kitade H, Ni Y, et al. Roles of chemokines and chemokine receptors in obesity-associated insulin resistance and nonalcoholic fatty liver disease. Biomolecules. 2015;5:1563–79.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Miura K, Yang L, Rooijen NV, et al. Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2. Am J Physiol Gastrointest Liver Physiol. 2012;302:1310–21.CrossRef Miura K, Yang L, Rooijen NV, et al. Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2. Am J Physiol Gastrointest Liver Physiol. 2012;302:1310–21.CrossRef
18.
Zurück zum Zitat Lu YC, Yeh WC, Ohashi PS. LPS/TLR4 Signal transduction pathway. Cytokine. 2008;42(2):145–51.CrossRefPubMed Lu YC, Yeh WC, Ohashi PS. LPS/TLR4 Signal transduction pathway. Cytokine. 2008;42(2):145–51.CrossRefPubMed
19.
Zurück zum Zitat Zhang X, Han J, Man K, et al. CXC chemokine receptor 3 promotes steatohepatitis in mice through mediating inflammatory cytokines, macrophages and autophagy. J Hepatol. 2016;64:160–70.CrossRefPubMed Zhang X, Han J, Man K, et al. CXC chemokine receptor 3 promotes steatohepatitis in mice through mediating inflammatory cytokines, macrophages and autophagy. J Hepatol. 2016;64:160–70.CrossRefPubMed
20.
Zurück zum Zitat Rasmussen AL, Wang IM, Shuhart MC, et al. Chronic immune activation is a distinguishing feature of liver and PBMC gene signatures from HCV/HIV-coinfected patients and may contribute to hepatic fibrogenesis. Virology. 2012;430:43–52.CrossRefPubMed Rasmussen AL, Wang IM, Shuhart MC, et al. Chronic immune activation is a distinguishing feature of liver and PBMC gene signatures from HCV/HIV-coinfected patients and may contribute to hepatic fibrogenesis. Virology. 2012;430:43–52.CrossRefPubMed
21.
Zurück zum Zitat Wang Q, Zheng Y, Huang Z, et al. Activated IL-23/IL-17 pathway closely correlates with increased Foxp3 expression in livers of chronic hepatitis B patients. BMC Immunol. 2011;25:12–25. Wang Q, Zheng Y, Huang Z, et al. Activated IL-23/IL-17 pathway closely correlates with increased Foxp3 expression in livers of chronic hepatitis B patients. BMC Immunol. 2011;25:12–25.
22.
Zurück zum Zitat Sakai Y, Honda M, Fujinaga H, et al. Common transcriptional signature of tumor-infiltrating mononuclear inflammatory cells and peripheral blood mononuclear cells in hepatocellular carcinoma patients. Cancer Res. 2008;68:10267–79.CrossRefPubMed Sakai Y, Honda M, Fujinaga H, et al. Common transcriptional signature of tumor-infiltrating mononuclear inflammatory cells and peripheral blood mononuclear cells in hepatocellular carcinoma patients. Cancer Res. 2008;68:10267–79.CrossRefPubMed
23.
Zurück zum Zitat His E, Huang CF, Dai CY, et al. Peripheral blood mononuclear cells microRNA predicts treatment outcome of hepatitis C virus genotype 1 infection. Antiviral Res. 2014;105:135–42.CrossRef His E, Huang CF, Dai CY, et al. Peripheral blood mononuclear cells microRNA predicts treatment outcome of hepatitis C virus genotype 1 infection. Antiviral Res. 2014;105:135–42.CrossRef
24.
Zurück zum Zitat Rau M, Schilling AK, Meertens J, et al. Progression from nonalcoholic fatty liver to nonalcoholic steatohepatitis is marked by a higher frequency of Th17 cells in the liver and an increased Th17/resting regulatory T cell ratio in peripheral blood and in the liver. J Immunol. 2016;196:97–105.CrossRefPubMed Rau M, Schilling AK, Meertens J, et al. Progression from nonalcoholic fatty liver to nonalcoholic steatohepatitis is marked by a higher frequency of Th17 cells in the liver and an increased Th17/resting regulatory T cell ratio in peripheral blood and in the liver. J Immunol. 2016;196:97–105.CrossRefPubMed
25.
Zurück zum Zitat Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116:1413–9.CrossRefPubMed Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116:1413–9.CrossRefPubMed
26.
Zurück zum Zitat Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55:2005–23.CrossRefPubMed Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55:2005–23.CrossRefPubMed
27.
Zurück zum Zitat McCarthy DA, Perry JD, Holburn CM, et al. Centrifugation of normal and rheumatoid arthritis blood on Ficoll-Hypaque and Ficoll-Nycodenz solution. J Immunol Meth. 1984;73:415–25.CrossRef McCarthy DA, Perry JD, Holburn CM, et al. Centrifugation of normal and rheumatoid arthritis blood on Ficoll-Hypaque and Ficoll-Nycodenz solution. J Immunol Meth. 1984;73:415–25.CrossRef
28.
Zurück zum Zitat Ruitenberg JJ, Mulder CB, Maino VC, et al. Vacutainer CPT and Ficoll density gradient separation perform equivalently in maintaining the quality and function of PBMC from HIV-seropositive blood samples. BMC Immunol. 2006;7:1–8.CrossRef Ruitenberg JJ, Mulder CB, Maino VC, et al. Vacutainer CPT and Ficoll density gradient separation perform equivalently in maintaining the quality and function of PBMC from HIV-seropositive blood samples. BMC Immunol. 2006;7:1–8.CrossRef
29.
Zurück zum Zitat Zimmermann E, Anty R, Tordjman J, et al. C-reactive protein levels in relation to various features of non-alcoholic fatty liver disease among obese patients. J Hepatol. 2011;55:660–5.CrossRefPubMed Zimmermann E, Anty R, Tordjman J, et al. C-reactive protein levels in relation to various features of non-alcoholic fatty liver disease among obese patients. J Hepatol. 2011;55:660–5.CrossRefPubMed
30.
Zurück zum Zitat Liu X, Wang Y, Ming Y, et al. S100A9: a potential biomarker for the progression of non-alcoholic fatty liver disease and the diagnosis of non-alcoholic steatohepatitis. PLoS One. 2014;10:1–14. Liu X, Wang Y, Ming Y, et al. S100A9: a potential biomarker for the progression of non-alcoholic fatty liver disease and the diagnosis of non-alcoholic steatohepatitis. PLoS One. 2014;10:1–14.
31.
Zurück zum Zitat Aida Y, Abe H, Tomita Y, et al. Serum cytokeratin 18 fragment level as a noninvasive biomarker for non-alcoholic fatty liver disease. Int J Clin Exp Med. 2014;7:4191–8.PubMedPubMedCentral Aida Y, Abe H, Tomita Y, et al. Serum cytokeratin 18 fragment level as a noninvasive biomarker for non-alcoholic fatty liver disease. Int J Clin Exp Med. 2014;7:4191–8.PubMedPubMedCentral
32.
Zurück zum Zitat Ajmera V, Perito ER, Bass NM, et al. Novel plasma biomarkers associated with liver disease severity in adults with nonalcoholic fatty liver disease. Hepatology. 2017;65:65–77.CrossRefPubMed Ajmera V, Perito ER, Bass NM, et al. Novel plasma biomarkers associated with liver disease severity in adults with nonalcoholic fatty liver disease. Hepatology. 2017;65:65–77.CrossRefPubMed
33.
Zurück zum Zitat Maina V, Sutti S, Locatelli I, et al. Bias in macrophage activation pattern influences non-alcoholic steatohepatitis (NASH) in mice. Clin Sci (Lond). 2012;122:545–53.CrossRef Maina V, Sutti S, Locatelli I, et al. Bias in macrophage activation pattern influences non-alcoholic steatohepatitis (NASH) in mice. Clin Sci (Lond). 2012;122:545–53.CrossRef
34.
Zurück zum Zitat Haukeland JW, Damås JK, Konopski Z, et al. Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J Hepatol. 2006;44:1167–74.CrossRefPubMed Haukeland JW, Damås JK, Konopski Z, et al. Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J Hepatol. 2006;44:1167–74.CrossRefPubMed
35.
Zurück zum Zitat Wobser H, Dorn C, Weiss TS, et al. Lipid accumulation in hepatocytes induces fibrogenic activation of hepatic stellate cells. Cell Res. 2009;19:996–1005.CrossRefPubMed Wobser H, Dorn C, Weiss TS, et al. Lipid accumulation in hepatocytes induces fibrogenic activation of hepatic stellate cells. Cell Res. 2009;19:996–1005.CrossRefPubMed
36.
Zurück zum Zitat Shin EC, Capone S, Cortese RJ, et al. The kinetics of hepatitis C virus-specific CD8 T-cell responses in the blood mirror those in the liver in acute hepatitis C virus infection. Virol. 2008;82:9782–8.CrossRef Shin EC, Capone S, Cortese RJ, et al. The kinetics of hepatitis C virus-specific CD8 T-cell responses in the blood mirror those in the liver in acute hepatitis C virus infection. Virol. 2008;82:9782–8.CrossRef
37.
Zurück zum Zitat Xu LL, Warren MK, Rose WL, et al. Human recombinant monocyte chemotactic protein and other C-C chemokines bind and induce directional migration of dendritic cells in vitro. J Leukoc Biol. 1996;60:365–71.CrossRefPubMed Xu LL, Warren MK, Rose WL, et al. Human recombinant monocyte chemotactic protein and other C-C chemokines bind and induce directional migration of dendritic cells in vitro. J Leukoc Biol. 1996;60:365–71.CrossRefPubMed
38.
Zurück zum Zitat Ito A, Suganami T, Miyamoto Y, et al. Role of MAPK phosphatase-1 in the induction of monocyte chemoattractant protein-1 during the course of adipocyte hypertrophy. J Biol Chem. 2007;282:25445–52.CrossRefPubMed Ito A, Suganami T, Miyamoto Y, et al. Role of MAPK phosphatase-1 in the induction of monocyte chemoattractant protein-1 during the course of adipocyte hypertrophy. J Biol Chem. 2007;282:25445–52.CrossRefPubMed
39.
Zurück zum Zitat Schoenborn JR, Wilson CB. Regulation of interferon-gamma during innate and adaptive immune responses. Adv Immunol. 2007;96:41–101.CrossRefPubMed Schoenborn JR, Wilson CB. Regulation of interferon-gamma during innate and adaptive immune responses. Adv Immunol. 2007;96:41–101.CrossRefPubMed
40.
Zurück zum Zitat McDonald PP, Russo MP, Ferrini S, et al. Interleukin-15 (IL-15) induces NF-κB activation and IL-8 production in human neutrophils. Blood. 1998;92:4828–35.PubMed McDonald PP, Russo MP, Ferrini S, et al. Interleukin-15 (IL-15) induces NF-κB activation and IL-8 production in human neutrophils. Blood. 1998;92:4828–35.PubMed
41.
Zurück zum Zitat Gao B, Radaeva S, Park O. Liver natural killer and natural killer T cells: immunobiology and emerging roles in liver diseases. J Leukoc Biol. 2009;86:513–28.CrossRefPubMedPubMedCentral Gao B, Radaeva S, Park O. Liver natural killer and natural killer T cells: immunobiology and emerging roles in liver diseases. J Leukoc Biol. 2009;86:513–28.CrossRefPubMedPubMedCentral
42.
Zurück zum Zitat Cepero YD, Lacraz G, Ghobadi F, et al. Interleukin-15-mediated inflammation promotes non-alcoholic fatty liver disease. Cytokine. 2016;82:102–11.CrossRef Cepero YD, Lacraz G, Ghobadi F, et al. Interleukin-15-mediated inflammation promotes non-alcoholic fatty liver disease. Cytokine. 2016;82:102–11.CrossRef
43.
Zurück zum Zitat Sun H, Liu D. Hydrodynamic delivery of interleukin 15 gene promotes resistance to high fat diet-induced obesity, fatty liver and improves glucose homeostasis. Gene Ther. 2015;22:341–7.CrossRefPubMed Sun H, Liu D. Hydrodynamic delivery of interleukin 15 gene promotes resistance to high fat diet-induced obesity, fatty liver and improves glucose homeostasis. Gene Ther. 2015;22:341–7.CrossRefPubMed
44.
Zurück zum Zitat Liao W, Lin JX, Leonard WJ. IL-2 family cytokines: new insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation. Curr Opin Immunol. 2011;23:598–604.CrossRefPubMedPubMedCentral Liao W, Lin JX, Leonard WJ. IL-2 family cytokines: new insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation. Curr Opin Immunol. 2011;23:598–604.CrossRefPubMedPubMedCentral
45.
Zurück zum Zitat Yang J, Murphy TL, Ouyang W, et al. Induction of interferon-gamma production in Th1 CD4+ T cells: evidence for two distinct pathways for promoter activation. Eur J Immunol. 1999;29:548–55.CrossRefPubMed Yang J, Murphy TL, Ouyang W, et al. Induction of interferon-gamma production in Th1 CD4+ T cells: evidence for two distinct pathways for promoter activation. Eur J Immunol. 1999;29:548–55.CrossRefPubMed
46.
Zurück zum Zitat Müller M, Carter S, Hofer MJ, et al. The chemokine receptor CXCR3 and its ligands CXCL9, CXCL10, and CXCL11 in neuroimmunity—a tale of conflict and conundrum. Neuropathol Appl Neurobiol. 2010;36:368–87.CrossRefPubMed Müller M, Carter S, Hofer MJ, et al. The chemokine receptor CXCR3 and its ligands CXCL9, CXCL10, and CXCL11 in neuroimmunity—a tale of conflict and conundrum. Neuropathol Appl Neurobiol. 2010;36:368–87.CrossRefPubMed
47.
Zurück zum Zitat Zhang X, Shen J, Man K, et al. CXCL10 plays a key role as an inflammatory mediator and a non-invasive biomarker of non-alcoholic steatohepatitis. J Hepatol. 2014;61:1365–75.CrossRefPubMed Zhang X, Shen J, Man K, et al. CXCL10 plays a key role as an inflammatory mediator and a non-invasive biomarker of non-alcoholic steatohepatitis. J Hepatol. 2014;61:1365–75.CrossRefPubMed
48.
Zurück zum Zitat Tomita K, Freeman BL, Bronk SF, et al. CXCL10-mediates macrophage, but not other innate immune cells-associated inflammation in murine nonalcoholic steatohepatitis. Sci Rep. 2016;28:1–13. Tomita K, Freeman BL, Bronk SF, et al. CXCL10-mediates macrophage, but not other innate immune cells-associated inflammation in murine nonalcoholic steatohepatitis. Sci Rep. 2016;28:1–13.
49.
Zurück zum Zitat Wasmuth HE, Lammert F, Zaldivar MM, et al. Antifibrotic effects of CXCL9 and its receptor CXCR3 in livers of mice and humans. Gastroenterology. 2009;137:309–19.CrossRefPubMed Wasmuth HE, Lammert F, Zaldivar MM, et al. Antifibrotic effects of CXCL9 and its receptor CXCR3 in livers of mice and humans. Gastroenterology. 2009;137:309–19.CrossRefPubMed
50.
Zurück zum Zitat Malefyt RW, Abrams J, Bennett B, et al. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med. 1991;174:1209–20.CrossRef Malefyt RW, Abrams J, Bennett B, et al. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med. 1991;174:1209–20.CrossRef
51.
Zurück zum Zitat Malefyt RW, Haanen J, Spits H, et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med. 1991;174:915–24.CrossRef Malefyt RW, Haanen J, Spits H, et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med. 1991;174:915–24.CrossRef
52.
Zurück zum Zitat Aste-Amezaga MA, Ma X, Sartori A, et al. Molecular mechanisms of the induction of IL-12 and its inhibition by IL-10. J Immunol. 1998;160:5936–44.PubMed Aste-Amezaga MA, Ma X, Sartori A, et al. Molecular mechanisms of the induction of IL-12 and its inhibition by IL-10. J Immunol. 1998;160:5936–44.PubMed
53.
Zurück zum Zitat Shi J, Wang H, Guan H, et al. IL-10 inhibits starvation-induced autophagy in hypertrophic scar fibroblasts via cross talk between the IL-10-IL-10R-STAT3 and IL-10-AKT-mTOR pathways. Cell Death Dis. 2016;10:21–33. Shi J, Wang H, Guan H, et al. IL-10 inhibits starvation-induced autophagy in hypertrophic scar fibroblasts via cross talk between the IL-10-IL-10R-STAT3 and IL-10-AKT-mTOR pathways. Cell Death Dis. 2016;10:21–33.
54.
Zurück zum Zitat Mizushima N. The role of the Atg1/ULK1 complex in autophagy regulation. Curr Opin Cell Biol. 2010;22:132–9.CrossRefPubMed Mizushima N. The role of the Atg1/ULK1 complex in autophagy regulation. Curr Opin Cell Biol. 2010;22:132–9.CrossRefPubMed
55.
Zurück zum Zitat Rodríguez AG, Mayoral R, Agra N, et al. Impaired autophagic flux is associated with increased endoplasmic reticulum stress during the development of NAFLD. Cell Death Dis. 2014;17:11–79. Rodríguez AG, Mayoral R, Agra N, et al. Impaired autophagic flux is associated with increased endoplasmic reticulum stress during the development of NAFLD. Cell Death Dis. 2014;17:11–79.
56.
Zurück zum Zitat Suzuki A, Kakisaka K, Suzuki Y, et al. c-Jun N-terminal kinase-mediated Rubicon expression enhances hepatocyte lipoapoptosis and promotes hepatocyte ballooning. World J Gastroenterol. 2016;22:6509–19.CrossRefPubMedPubMedCentral Suzuki A, Kakisaka K, Suzuki Y, et al. c-Jun N-terminal kinase-mediated Rubicon expression enhances hepatocyte lipoapoptosis and promotes hepatocyte ballooning. World J Gastroenterol. 2016;22:6509–19.CrossRefPubMedPubMedCentral
57.
58.
Zurück zum Zitat Li BH, He FP, Yang X, et al. Steatosis-induced CCL5 contributes to early-stage liver fibrosis in nonalcoholic fatty liver disease. Transl Res. 2017;180:103–17.CrossRefPubMed Li BH, He FP, Yang X, et al. Steatosis-induced CCL5 contributes to early-stage liver fibrosis in nonalcoholic fatty liver disease. Transl Res. 2017;180:103–17.CrossRefPubMed
59.
Zurück zum Zitat Ajuebor MN, Carey JA, Swain MG. CCR5 in T cell-mediated liver diseases: what’s going on? J Immunol. 2006;177:2039–45.CrossRefPubMed Ajuebor MN, Carey JA, Swain MG. CCR5 in T cell-mediated liver diseases: what’s going on? J Immunol. 2006;177:2039–45.CrossRefPubMed
60.
Zurück zum Zitat Seki E, Minicis SD, Gwak GY, et al. CCR1 and CCR5 promote hepatic fibrosis in mice. J Clin Invest. 2009;119:1858–70.PubMedPubMedCentral Seki E, Minicis SD, Gwak GY, et al. CCR1 and CCR5 promote hepatic fibrosis in mice. J Clin Invest. 2009;119:1858–70.PubMedPubMedCentral
61.
Zurück zum Zitat Lefebvre E, Moyle G, Reshef R, et al. Antifibrotic effects of the dual CCR2/CCR5 antagonist Cenicriviroc (CVC) in animal models of liver and kidney fibrosis. PLoS ONE. 2016;11:1–19. Lefebvre E, Moyle G, Reshef R, et al. Antifibrotic effects of the dual CCR2/CCR5 antagonist Cenicriviroc (CVC) in animal models of liver and kidney fibrosis. PLoS ONE. 2016;11:1–19.
62.
Zurück zum Zitat Satoh T, Nakagawa K, Sugihara F, et al. Identification of an atypical monocyte and committed progenitor involved in fibrosis. Nature. 2017;541:96–101.CrossRefPubMed Satoh T, Nakagawa K, Sugihara F, et al. Identification of an atypical monocyte and committed progenitor involved in fibrosis. Nature. 2017;541:96–101.CrossRefPubMed
Metadaten
Titel
Noninvasive diagnostic criteria for nonalcoholic steatohepatitis based on gene expression levels in peripheral blood mononuclear cells
verfasst von
Akira Kado
Takeya Tsutsumi
Kenichiro Enooku
Hidetaka Fujinaga
Kazuhiko Ikeuchi
Kazuya Okushin
Kyoji Moriya
Hiroshi Yotsuyanagi
Kazuhiko Koike
Publikationsdatum
04.03.2019
Verlag
Springer Japan
Erschienen in
Journal of Gastroenterology / Ausgabe 8/2019
Print ISSN: 0944-1174
Elektronische ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-019-01565-x

Weitere Artikel der Ausgabe 8/2019

Journal of Gastroenterology 8/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.